Stock Yearly Return 2021
Start date: 01/04/2021
End date: 12/31/2021
Start price/share: $6.78
End price/share: $4.33
Dividends collected/share: $0.00
Total return: -36.14%
CTMX Average Annual Return: -36.54%
Starting investment: $10,000.00
Ending investment: $6,386.00
Years: 0.99


CTMX average annual return is presented with the assumption of reinvestments of any dividends on ex-date.
Compare CTMX average annual return versus benchmarks:

S&P Average Annual Return
Dow Average Annual Return
Nasdaq 100 Average Annual Return
Russell 2000 Average Annual Return
Gold Average Annual Return
10 Year Treasury Average Annual Return
Growth of $10,000.00
Without Dividends Reinvested Into CTMX


Also see:
CTMX YTD return
CTMX average annual return 10 years
CytomX Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company. Co. is developing an antibody-based therapeutics created using its Probody® therapeutic technology platform. Co.'s products include: Praluzatamab ravtansine, an activated antibody-drug conjugates (ADC) directed against CD166, a tumor target previously considered undruggable due to its high expression on normal tissues; CX-2029, an activated ADC targeting CD71, also known as the transferrin receptor 1; and BMS-986249, which is a Probody version of ipilimumab that developed into a randomized Phase 2 study in combination with the PD-1 inhibitor nivolumab in patients with metastatic melanoma. The CTMX stock yearly return is shown above.

The yearly return on the CTMX stock yearly return page and across the coverage universe of our site, is a measure of the annual return over the calendar year 2021 for the given stock. When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is more than just the change in price if that instrument pays a dividend or coupon.

One way to factor dividends into the return is simply to count them as cash — we don't do that here. Instead, our website aims to empower investors by performing the CTMX annual return calculation with any dividends reinvested as applicable (on ex-dates).
Quotes delayed 20 minutes

Email EnvelopeFree CTMX Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold Stocks in the S&P
10 Most Overbought Stocks in the S&P
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Don't Forget Dividends in Average Annual Return!


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
CytomX Therapeutics (CTMX) is categorized under the Healthcare sector; to help you further research average annual return performance across stocks, below are some other companies in the same sector:

CTSO Average Annual Return
CTXR Average Annual Return
CUE Average Annual Return
CUTR Average Annual Return
CVRX Average Annual Return
CVS Average Annual Return
CWBR Average Annual Return
CYCC Average Annual Return
CYCN Average Annual Return
CYH Average Annual Return
More Healthcare companies »

 

CTMX Stock Yearly Return 2021 | www.AverageAnnualReturn.com | Copyright © 2021 - 2022, All Rights Reserved

Nothing in AverageAnnualReturn.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.